MoonLake Q2 FY26 net loss widens 10.3% to $61.81 million
Reuters2026/08/10 11:50- MoonLake Immunotherapeutics posted a net loss of $61.81 million, widening 10.3% year over year in the quarter ended June 30, 2026.
- Operating loss widened 1.6% to $61.66 million as research and development spending edged up 0.9% to $50.22 million.
- General and administrative costs rose 4.6% to $11.44 million, while other income fell 62% to $2.58 million.
- Cash, cash equivalents, and short-term marketable securities totaled $537 million at June 30, funding operations to mid-2028.
- MoonLake targets a BLA submission for sonelokimab in hidradenitis suppurativa at end-Q3 2026, aiming for a U.S. launch in H2 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Oil jumps more than 2% after US attack on Iran's Larak island
After Waller's hawkish speech, the market focuses on "rate hikes", but Morgan Stanley says balance sheet reduction is more likely.
After the Jackson Hole meeting, the market's focus has shifted to interest rate hike expectations. However, Morgan Stanley economist Carpenter pointed out that Walsh's long-standing stance on reducing the $7 trillion balance sheet should not be overlooked. It is expected that the Federal Reserve may begin a balance sheet reduction of more than $1.5 trillion next year, partially replacing rate hikes.
BTC surpasses $78,000
AON plans to acquire USI for 17 billion USD, aiming at the SME insurance brokerage market.
According to informed sources, AON.US is close to reaching a deal valued at around $17 billion, including debt, to acquire insurance brokerage USI from private equity firm KKR.
Crypto prices
More
